BMS Signs a Research Collaboration with DarwinHealth to Discover Novel Cancer Target Initiative

Shots:

• DarwinHealth will receive an upfront and eligible to receive as a commercial milestone, as part of the NCTI collaboration
• The focus of the collaboration is to identify NCTs across tumor subtypes for different cancer types by using quantitative systems biology-based algorithms, databases, and technologies and leads to the development of drugs with multi-subtype indications
• Following the NCTs discovery, BMS gets the proprietary information from DarwinHealth in its drug databases, including specific tumor analyses from MRs or MRUMs of distinct tumor subtypes

Click here to­ read full press release/ article | Ref: PRNewswire | Image: BMS